i-Lumen Scientific’s mission is to develop innovative technologies which are clinically proven to be safe and effective in the improvement of vision in patients with dry AMD.
John VeLure, Chief Executive Officer
Mr. VeLure hwas previously President and Founder of Neurotech, a surface neurostimulation company, specializing in orthopedic therapies, which was acquired by Theragen in 2015. He also served as Senior Director at Compex Technologies, a world leader in surface neurostimulation, and led the growth of the medical business, which was acquired by ReAble Therapeutics. Mr. Velure was also Vice President of Sales and Marketing for American Medtech, a urology company that developed and distributed Class II medical devices for ED and led the sale of the company to Pos-T-Vac, a leader in ED devices.
Meredith Mundy, Vice President Clinical Research
Ms. Mundy has 20+ years of experience in operational management for small to large businesses. She has focused on clinical operations for early-stage medical device companies, during the last 10 years. These medical devices have included surface neural stimulation and modulation, ENT applications, systems, software, and implantables. Ms. Mundy was recently with Stryker Corporation, as part of the acquisition of Arrinex, Inc., along with the previous acquisition of Spirox, Inc., where she both designed and managed clinical study programs for submissions and post-market surveillance.
BOARD OF DIRECTORS
Vision with AMD
Chris Pulling, Director
Mr. Pulling is CEO of the Ophthalmic Clinical-stage Medical Device start-up MicroOptx and has over 30 years experience in the medical device and clinical and regulatory fields. MicroOptx has raised approximately $24.5M in capital, including $17M in Q2-2019, and initiated a US pivotal clinical study in Q3-2019. Chris was previously CEO of The Integra Group, a contract medical research organization he founded in 2002 and later sold to the world's largest contract organization in the medical device sector. At that time, Integra was assisting over 400 pre-market medical device companies in all aspects of research and development. Chris was personally involved in over 30 original PMA approvals and even more 510(k) clearances. Prior to Integra, he built and ran Medtronic’s Cardiac Rhythm Management's Biostatistics function. Chris has an MS in Biostatistics from the University of Minnesota and was recently just the fourth recipient of the U of MN’s School of Public Health Alumni Innovator Award.
Stella Robertson, PhD, Director
Dr. Robertson has over 25 years of experience in pharmaceutical Research and Development, including R&D strategies, project management, clinical trials, regulatory filings for US and international registrations, product launch, market support, translational medicine, and medical communication. Currently, Dr. Robertson is a member of Cowtown Angels and the owner of Arrochar Consulting LLC. She formerly was a Vice President in Research and Development at Alcon Laboratories, Inc., a Division of Novartis, where she grew and led organizations that were responsible for the ophthalmic pipeline, designing and developing ophthalmic and otic pharmaceuticals and medical devices, achieving over fifteen global product approvals. She received a PhD in Biology-Immunology from Johns Hopkins University, is an adjunct member of the Ophthalmology Department of UTHSCD Southwestern Medical School, and an Entrepreneur in Residence with Bios Partners at UNTHSC of Fort Worth. She holds a number of patents and is the author or co-author of over 50 publications.
Robert Warner, Director
Mr. Warner is the former President of Alcon Laboratories. Mr. Warner has extensive US and international ophthalmic sales and marketing experience, as well as general management, mergers, and acquisitions experience. He was responsible for Alcon’s $4.5 Billion medical device, pharmaceutical, and consumer products businesses for the US and Canada. Prior to that he ran the Latin American and Canadian businesses. Mr. Warner has significant medical device and ophthalmic business management, strategy, expansion, marketing, and sales experience, which will strongly contribute to building the Company.
Michael Glover, Director
Mr. Glover is a lawyer practicing in areas including corporate litigation, securities, corporate governance, insurance, officer and director liability and patent and trademark litigation. Mr. Glover has sat on multiple boards of corporations and has acted as general counsel on several others. Mr. Glover’s extensive legal experience and historical knowledge of the Company and its technology provides a valuable resource for the Board in its decision making and strategic planning for the future of the Company.